journal
https://read.qxmd.com/read/38558246/long-noncoding-rna-tug1-promotes-cisplatin-resistance-in-ovarian-cancer-via-upregulation-of-dna-polymerase-eta
#21
JOURNAL ARTICLE
Ryosuke Sonobe, Peng Yang, Miho M Suzuki, Keiko Shinjo, Kenta Iijima, Nobuhiro Nishiyama, Kanjiro Miyata, Kazunori Kataoka, Hiroaki Kajiyama, Yutaka Kondo
Chemoresistance is a major cause of high mortality and poor survival in patients with ovarian cancer (OVCA). Understanding the mechanisms of chemoresistance is urgently required to develop effective therapeutic approaches to OVCA. Here, we show that expression of the long noncoding RNA, taurine upregulated gene 1 (TUG1), is markedly upregulated in samples from OVCA patients who developed resistance to primary platinum-based therapy. Depletion of TUG1 increased sensitivity to cisplatin in the OVCA cell lines, SKOV3 and KURAMOCHI...
April 1, 2024: Cancer Science
https://read.qxmd.com/read/38549229/application-of-prime-editing-system-to-introduce-tp53-r248q-hotspot-mutation-in-acute-lymphoblastic-leukemia-cell-line
#22
JOURNAL ARTICLE
Thao Nguyen, Tomomi Aida, Yuka Iijima-Yamashita, Minori Tamai, Akiko Nagamachi, Keiko Kagami, Chiaki Komatsu, Shin Kasai, Koshi Akahane, Kumiko Goi, Toshiya Inaba, Masashi Sanada, Takeshi Inukai
In childhood acute lymphoblastic leukemia (ALL), TP53 gene mutation is associated with chemoresistance in a certain population of relapsed cases. To directly verify the association of TP53 gene mutation with chemoresistance of relapsed childhood ALL cases and improve their prognosis, the development of appropriate human leukemia models having TP53 mutation in the intrinsic gene is required. Here, we sought to introduce R248Q hotspot mutation into the intrinsic TP53 gene in an ALL cell line, 697, by applying a prime editing (PE) system, which is a versatile genome editing technology...
March 28, 2024: Cancer Science
https://read.qxmd.com/read/38538548/identification-of-barriers-to-implementation-of-precision-oncology-in-patients-with-rare-cancers
#23
JOURNAL ARTICLE
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Established treatment options for rare cancers are limited by the small number of patients. The current comprehensive genomic profiling (CGP) testing might not fully exploit opportunities for precision oncology in patients with rare cancers. Therefore, we aimed to explore the factors associated with CGP testing utility in rare cancers and identify barriers to implementing precision oncology. Patients who underwent CGP testing at our institution between September 2019 and June 2021 were enrolled in this retrospective study...
March 27, 2024: Cancer Science
https://read.qxmd.com/read/38538295/expression-of-concern-hydroxychavicol-a-piper-betle-leaf-component-induces-apoptosis-of-cml-cells-through-mitochondrial-reactive-oxygen-species-dependent-jnk-and-endothelial-nitric-oxide-synthase-activation-and-overrides-imatinib-resistance
#24
https://read.qxmd.com/read/38532284/impacts-of-tissue-context-on-extracellular-vesicles-mediated-cancer-host-cell-communications
#25
REVIEW
Nao Nishida-Aoki, Takahiro Ochiya
Tumor tissue is densely packed with cancer cells, non-cancerous cells, and ECM, forming functional structures. Cancer cells transfer extracellular vesicles (EVs) to modify surrounding normal cells into cancer-promoting cells, establishing a tumor-favorable environment together with other signaling molecules and structural components. Such tissue environments largely affect cancer cell properties, and so as EV-mediated cellular communications within tumor tissue. However, current research on EVs focuses on functional analysis of vesicles isolated from the liquid phase, including cell culture supernatants and blood draws, 2D-cultured cell assays, or systemic analyses on animal models for biodistribution...
March 26, 2024: Cancer Science
https://read.qxmd.com/read/38531808/implementable-assay-for-monitoring-minimum-residual-disease-after-radical-treatment-for-colorectal-cancer
#26
JOURNAL ARTICLE
Takafumi Nakano, Seiichiro Takao, Katsushi Dairaku, Naoki Uno, Siew-Kee Amanda Low, Masahiro Hashimoto, Yasuo Tsuda, Yuichi Hisamatsu, Takeo Toshima, Yusuke Yonemura, Takaaki Masuda, Ken Eto, Toru Ikegami, Yosuke Fukunaga, Atsushi Niida, Satoshi Nagayama, Koshi Mimori
Considering the cost and invasiveness of monitoring postoperative minimal residual disease (MRD) of colorectal cancer (CRC) after adjuvant chemoradiotherapy (ACT), we developed a favorable approach based on methylated circulating tumor DNA to detect MRD after radical resection. Analyzing the public database, we identified the methylated promoter regions of the genes FGD5, GPC6, and MSC. Using digital polymerase chain reaction (dPCR), we termed the "amplicon of methylated sites using a specific enzyme" assay as "AMUSE...
March 26, 2024: Cancer Science
https://read.qxmd.com/read/38528657/microsatellite-instability-a-2024-update
#27
REVIEW
Hiroyuki Yamamoto, Yoshiyuki Watanabe, Hiroyuki Arai, Kumiko Umemoto, Keisuke Tateishi, Yu Sunakawa
Deficient mismatch repair (dMMR) results in microsatellite instability (MSI), a pronounced mutator phenotype. High-frequency MSI (MSI-H)/dMMR is gaining increasing interest as a biomarker for advanced cancer patients to determine their eligibility for immune checkpoint inhibitors (ICIs). Various methods based on next-generation sequencing (NGS) have been developed to assess the MSI status. Comprehensive genomic profiling (CGP) testing can precisely ascertain the MSI status as well as genomic alterations in a single NGS test...
March 25, 2024: Cancer Science
https://read.qxmd.com/read/38527308/molecular-subtypes-of-lung-adenocarcinoma-present-distinct-immune-tumor-microenvironments
#28
JOURNAL ARTICLE
Hironori Fukuda, Kosuke Arai, Hideaki Mizuno, Yukari Nishito, Noriko Motoi, Yasuhito Arai, Nobuyoshi Hiraoka, Tatsuhiro Shibata, Yukiko Sonobe, Yoko Kayukawa, Eri Hashimoto, Mina Takahashi, Etsuko Fujii, Toru Maruyama, Kenta Kuwabara, Takashi Nishizawa, Yukihiro Mizoguchi, Yukihiro Yoshida, Shun-Ichi Watanabe, Makiko Yamashita, Shigehisa Kitano, Hiromi Sakamoto, Yuki Nagata, Risa Mitsumori, Kouichi Ozaki, Shumpei Niida, Yae Kanai, Akiyoshi Hirayama, Tomoyoshi Soga, Keisuke Tsukada, Nami Yabuki, Mei Shimada, Takehisa Kitazawa, Osamu Natori, Noriaki Sawada, Atsuhiko Kato, Teruhiko Yoshida, Kazuki Yasuda, Atsushi Ochiai, Hiroyuki Tsunoda, Kazunori Aoki
Overcoming resistance to immune checkpoint inhibitors is an important issue in patients with non-small-cell lung cancer (NSCLC). Transcriptome analysis shows that adenocarcinoma can be divided into three molecular subtypes: terminal respiratory unit (TRU), proximal proliferative (PP), and proximal inflammatory (PI), and squamous cell carcinoma (LUSQ) into four. However, the immunological characteristics of these subtypes are not fully understood. In this study, we investigated the immune landscape of NSCLC tissues in molecular subtypes using a multi-omics dataset, including tumor-infiltrating leukocytes (TILs) analyzed using flow cytometry, RNA sequences, whole exome sequences, metabolomic analysis, and clinicopathologic findings...
March 25, 2024: Cancer Science
https://read.qxmd.com/read/38523358/cancer-specific-risk-prediction-with-a-serum-microrna-signature
#29
JOURNAL ARTICLE
Janhavi R Raut, Megha Bhardwaj, Ben Schöttker, Bernd Holleczek, Petra Schrotz-King, Hermann Brenner
We recently derived and validated a serum-based microRNA risk score (miR-score) that predicted colorectal cancer (CRC) occurrence with very high accuracy within 14 years of follow-up in a population-based cohort study from Germany (ESTHER cohort). Here, we aimed to evaluate associations of the CRC-specific miR-score with the risk of developing other common cancers, including female breast cancer (BC), lung cancer (LC), and prostate cancer (PC), in the ESTHER cohort. MicroRNAs (miRNAs) were profiled by quantitative real-time PCR in serum samples collected at baseline from randomly selected incident cases of BC (n = 90), LC (n = 88), and PC (n = 93) and participants without diagnosis of CRC, LC, BC, or PC (controls, n = 181) until the end of the 17-year follow-up...
March 24, 2024: Cancer Science
https://read.qxmd.com/read/38508217/wtap-induced-n-6-methyladenosine-of-pd-l1-blocked-t-cell-mediated-antitumor-activity-under-hypoxia-in-colorectal-cancer
#30
JOURNAL ARTICLE
Qi-Zhi Liu, Nan Zhang, Jun-Yi Chen, Min-Jun Zhou, De-Hua Zhou, Zhuo Chen, Zhen-Xing Huang, Yu-Xiang Xie, Guang-Lei Qiao, Xiao-Huang Tu
N6 -Methyladenosine (m6 A) is a important process regulating gene expression post-transcriptionally. Programmed death ligand 1 (PD-L1) is a major immune inhibitive checkpoint that facilitates immune evasion and is expressed in tumor cells. In this research we discovered that Wilms' tumor 1-associated protein (WTAP) degradation caused by ubiquitin-mediated cleavage in cancer cells (colorectal cancer, CRC) under hypoxia was inhibited by Pumilio homolog 1 (PUM1) directly bound to WTAP. WTAP enhanced PD-L1 expression in a way that was m6 A-dependent...
March 20, 2024: Cancer Science
https://read.qxmd.com/read/38507574/correction-to-phytochemical-library-screening-reveals-betulinic-acid-as-a-novel-skp2-scf-e3-ligase-inhibitor-in-non-small-cell-lung-cancer
#31
(no author information available yet)
No abstract text is available yet for this article.
March 20, 2024: Cancer Science
https://read.qxmd.com/read/38498976/autologous-hsct-with-novel-agent-based-induction-and-consolidation-followed-by-lenalidomide-maintenance-for-untreated-multiple-myeloma
#32
JOURNAL ARTICLE
Yasuo Mori, Jun Takizawa, Yuna Katsuoka, Naoki Takezako, Koji Nagafuji, Hiroshi Handa, Junya Kuroda, Kazutaka Sunami, Tomohiko Kamimura, Ryosuke Ogawa, Yoshikane Kikushige, Mine Harada, Koichi Akashi, Toshihiro Miyamoto
Triplet regimen comprising proteasome inhibitors, immunomodulatory drugs, and dexamethasone (DEX) is a recommended induction/consolidation therapy for multiple myeloma (MM) patients eligible for transplant. In this Japanese phase II study conducted from 2017 to 2019, newly diagnosed MM patients aged 20-65 received four induction cycles with bortezomib (Bor), lenalidomide (Len), and DEX (VRD), followed by Bor and high-dose melphalan with autologous stem cell rescue. Subsequently, they underwent four consolidation cycles with carfilzomib, Len, and DEX (KRD), followed by Len maintenance until disease progression...
March 18, 2024: Cancer Science
https://read.qxmd.com/read/38497363/correction-to-role-of-tumor-necrosis-factor-%C3%AE-and-its-receptors-in-human-benign-breast-lesions-and-tumors-in-situ-and-infiltrative
#33
(no author information available yet)
No abstract text is available yet for this article.
March 18, 2024: Cancer Science
https://read.qxmd.com/read/38494608/enhanced-lipid-biosynthesis-in-oral-squamous-cell-carcinoma-cancer-associated-fibroblasts-contributes-to-tumor-progression-role-of-il8-akt-p-acly-axis
#34
JOURNAL ARTICLE
Pan Liu, Yue Wang, Xiang Li, Zhenan Liu, Yunqing Sun, Hanzhe Liu, Zhe Shao, Erhui Jiang, Xiaocheng Zhou, Zhengjun Shang
Lipid metabolic reprogramming of tumor cells has been proven to play a critical role in tumor initiation and development. However, lipid metabolism in cancer-associated fibroblasts (CAFs) has rarely been studied, particularly in CAFs of oral squamous cell carcinoma (OSCC). Additionally, the molecular mechanism by which tumor cells regulate lipid metabolism in fibroblasts is unclear. In this study, we found that phosphorylated ATP citrate lyase (p-ACLY), a key lipid metabolic enzyme, was upregulated in OSCC CAFs...
March 17, 2024: Cancer Science
https://read.qxmd.com/read/38494600/tumor-suppressive-role-of-the-epigenetic-master-regulator-brd3-in-colorectal-cancer
#35
JOURNAL ARTICLE
Masahiro Hashimoto, Takaaki Masuda, Yusuke Nakano, Taro Tobo, Hideyuki Saito, Kensuke Koike, Junichi Takahashi, Tadashi Abe, Yuki Ando, Yuki Ozato, Kiyotaka Hosoda, Satoshi Higuchi, Yuichi Hisamatsu, Takeo Toshima, Yusuke Yonemura, Tsuyoshi Hata, Mamoru Uemura, Hidetoshi Eguchi, Yuichiro Doki, Masaki Mori, Koshi Mimori
Bromodomain and extraterminal domain (BET) family proteins are epigenetic master regulators of gene expression via recognition of acetylated histones and recruitment of transcription factors and co-activators to chromatin. Hence, BET family proteins have emerged as promising therapeutic targets in cancer. In this study, we examined the functional role of bromodomain containing 3 (BRD3), a BET family protein, in colorectal cancer (CRC). In vitro and vivo analyses using BRD3-knockdown or BRD3-overexpressing CRC cells showed that BRD3 suppressed tumor growth and cell cycle G1/S transition and induced p21 expression...
March 17, 2024: Cancer Science
https://read.qxmd.com/read/38487949/efficacy-and-predictors-of-immune-checkpoint-inhibitors-in-patients-with-gallbladder-cancer
#36
JOURNAL ARTICLE
Zhuo Cheng, Cheng Yang, Qian Zhao, Jingjiao Zhong, Jin Zhang, Riming Jin, Yao Li, Na Ta, Dong Wu, Zhengang Yuan, Wen Sun, Ruoyu Wang
Immune checkpoint inhibitors (ICIs) have shown promising efficacy in multiple cancers including biliary tract cancers (BTCs). However, the data focusing on the efficacy of ICIs in patients with gallbladder cancer (GBC) is still limited. In this study, we aim to assess the efficacy of ICIs in GBC and explore the clinicopathologic and molecular markers associated with ICI benefit. We retrospective analyzed 69 GBC patients who had received ICI therapy between January 2016 and December 2020. Tumor samples were obtained for genomic sequencing and immunohistochemical analysis...
March 15, 2024: Cancer Science
https://read.qxmd.com/read/38480904/mfn2-suppresses-the-accumulation-of-lipid-droplets-and-the-progression-of-clear-cell-renal-cell-carcinoma
#37
JOURNAL ARTICLE
Zhiduan Cai, Wenjun Luo, Haoran Wang, Rui Zhu, Yaoji Yuan, Xiangyu Zhan, Mengyuan Xie, Haoquan Zhuang, Haoyu Chen, Yuyu Xu, Xiezhao Li, Leyuan Liu, Guibin Xu
Dissolving the lipid droplets in tissue section with alcohol during a hematoxylin and eosin (H&E) stain causes the tumor cells to appear like clear soap bubbles under a microscope, which is a key pathological feature of clear cell renal cell carcinoma (ccRCC). Mitochondrial dynamics have been reported to be closely associated with lipid metabolism and tumor development. However, the relationship between mitochondrial dynamics and lipid metabolism reprogramming in ccRCC remains to be further explored. We conducted bioinformatics analysis to identify key genes regulating mitochondrial dynamics differentially expressed between tumor and normal tissues and immunohistochemistry and Western blot to confirm...
March 13, 2024: Cancer Science
https://read.qxmd.com/read/38480477/faxc-interacts-with-anxa2-and-src-in-mitochondria-and-promotes-tumorigenesis-in-cholangiocarcinoma
#38
JOURNAL ARTICLE
Haruna Fujimori, Mao Shima-Nakamura, Shin-Ichiro Kanno, Rie Shibuya-Takahashi, Mai Mochizuki, Masamichi Mizuma, Michiaki Unno, Yuta Wakui, Makoto Abue, Wataru Iwai, Daisuke Fukushi, Kennich Satoh, Kazunori Yamaguchi, Norihisa Shindo, Jun Yasuda, Keiichi Tamai
Cholangiocarcinoma (CCA) is one of the most difficult malignancies to treat as the therapeutic options are limited. Although several driver genes have been identified, most remain unknown. In this study, we identified a failed axon connection homolog (FAXC), whose function is unknown in mammals, by analyzing serially passaged CCA xenograft models. Knockdown of FAXC reduced subcutaneous tumorigenicity in mice. FAXC was bound to annexin A2 (ANXA2) and c-SRC, which are tumor-promoting genes. The FAXC/ANXA2/c-SRC complex forms in the mitochondria...
March 13, 2024: Cancer Science
https://read.qxmd.com/read/38480462/alix-normalized-exosomal-programmed-death-ligand-1-analysis-in-urine-enables-precision-monitoring-of-urothelial-cancer
#39
JOURNAL ARTICLE
Hyun-Kyung Woo, Juhee Park, Kyung Hwan Kim, Ja Yoon Ku, Hong Koo Ha, Yoon-Kyoung Cho
Anti-programmed death-ligand 1 (PD-L1) Ab-based therapies have demonstrated potential for treating metastatic urothelial cancer with high PD-L1 expression. Urinary exosomes are promising biomarkers for liquid biopsy, but urine's high variability requires normalization for accurate analysis. This study proposes using the PD-L1/Alix ratio to normalize exosomal PD-L1 signal intensity with Alix, an internal exosomal protein less susceptible to heterogeneity concerns than surface protein markers. Extracellular vesicles were isolated using ExoDisc and characterized using various methods, including ExoView to analyze tetraspanins, PD-L1, and Alix on individual exosomes...
March 13, 2024: Cancer Science
https://read.qxmd.com/read/38480275/upregulation-of-hla-ii-related-to-lag-3-cd4-t-cell-infiltration-is-associated-with-patient-outcome-in-human-glioblastoma
#40
JOURNAL ARTICLE
Wenli Guo, Daijun Peng, Yuee Liao, Lei Lou, Moran Guo, Chen Li, Wangyang Yu, Xiaoxi Tian, Guohui Wang, Ping Lv, Jing Zuo, Haitao Shen, Yuehong Li
Glioblastoma (GBM) is the most common malignant diffuse glioma of the brain. Although immunotherapy with immune checkpoint inhibitors (ICIs), such as programmed cell death protein (PD)-1/PD ligand-1 inhibitors, has revolutionized the treatment of several cancers, the clinical benefit in GBM patients has been limited. Lymphocyte-activation gene 3 (LAG-3) binding to human leukocyte antigen-II (HLA-II) plays an essential role in triggering CD4+ T cell exhaustion and could interfere with the efficiency of anti-PD-1 treatment; however, the value of LAG-3-HLA-II interactions in ICI immunotherapy for GBM patients has not yet been analyzed...
March 13, 2024: Cancer Science
journal
journal
40398
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.